Skip to NavigationSkip to content

Eloxatin and Campto gain new NICE approval

Published on 13/04/05 at 04:58pm

NICE has recommended two more chemotherapy drugs for the first-line treatment of advanced colorectal cancer.

The institute said that Sanofi-Aventis' Eloxatin (oxaliplatin) and Pfizer's Campto (irinotecan) should be considered as first-line treatment for the disease.

It has updated its earlier approval of Eloxatin and Campto following a new appraisal of the treatments.

NICE concluded that both treatments were cost-effective and that combining the colorectal cancer drugs with the standard therapy can improve survival rates in patients.

It has recommended that Eloxatin be used in combination with conventional 5-fluorouracil and folinic acid as a first-line therapy. It has issued the same recommendation for Campto as well as advising its use alone as a second-line therapy.

The updated approvals bring treatment for patients in England and Wales in line with the rest of Europe.

Jola Gore-Booth, chief executive of Colon Cancer Concern, told the BBC: "This is the biggest and the most exciting news we have had for patients with bowel cancer in the last 50 years."

The institute will make its final recommendation following a second Appraisal Committee meeting scheduled for 11 May.

Nearly 100 people are diagnosed with colorectal cancer every day, with 50 of these in the advanced stage of the disease.









Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches